Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Omnicell Inc(OMCL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OMCL
09/25/2026: OMCL (1-star) is currently NOT-A-BUY. Pass it for now.
Omnicell Inc is a specialized health care technology company focusing on medication management automation and digital pharmacy services. The company benefits from a strong installed base in hospitals, which provides stable service opportunities and high customer switching costs. Its primary growth strategy centers on the 'Autonomous Pharmacy' vision, transitioning toward recurring, cloud-based software revenue. However, the company faces risks from cyclical hospital capital spending, intense competition from large medical device manufacturers, and the complex execution of its digital transformation. It may suit growth-oriented investors interested in healthcare digitization, though potential investors should monitor hospital budget trends and the progress of its SaaS transition.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to digital health trends but faces cyclicality in hospital spending. |
| Momentum investor | Weak fit | Stock performance often fluctuates based on hospital capital budget cycles rather than short-term price momentum. |
| Value investor | Mixed fit | Valuation depends heavily on the long-term success of the SaaS transition versus traditional hardware sales. |
| Dividend investor | Weak fit | Omnicell does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Volatility in healthcare IT spending and integration risks make this a higher-beta asset. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is sensitive to shifts in healthcare spending and broader economic cycles. |
| Valuation risk | Medium | Investors must weigh the growth potential of software services against the legacy hardware business. |
| Competition risk (Med-Tech/Software incumbents) | High | Competing against established giants like BD requires constant innovation. |
| Business quality | Medium | High customer switching costs provide a moat, though execution on digital transformation is critical. |
| Dividend income | Low / none | The company does not provide income through dividends. |
| Execution risk | Medium / high | Successfully managing the transition to a recurring revenue model is vital for long-term margins. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -15.91% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.50B USD | Price to earnings Ratio 39.32 | 1Y Target Price 57.86 |
Price to earnings Ratio 39.32 | 1Y Target Price 57.86 | ||
Volume (30-day avg) 611.8K shares | Beta 0.97 | 52 Weeks Range 29.06 - 55.00 | Updated Date 09/25/2026 |
52 Weeks Range 29.06 - 55.00 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Automation and Analytics | Automated dispensing cabinets and inventory software for hospitals. | The core business selling hardware and software to automate hospital drug management. |
| Pharmacy Services | Adherence solutions and software for retail/long-term care pharmacies. | Services that help pharmacies improve patient drug adherence and operational workflow. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 39.32 | Forward PE 29.5 | Enterprise Value 1.41B | Price to Sales(TTM) 1.2 |
Enterprise Value 1.41B | Price to Sales(TTM) 1.2 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA 9.82 | Shares Outstanding 45.48M | Shares Floating 44.38M |
Shares Outstanding 45.48M | Shares Floating 44.38M | ||
Percent Insiders 2.15 | Percent Institutions 108.12 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Omnicell Inc
Exchange NASDAQ | Headquarters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3485 | Website https://www.omnicell.com |
Full time employees 3485 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.